Oragenics gets NYSE American deficiency notice over stockholders’ equity shortfall
OGEN•FDA meeting package response and IND target
Separately, the FDA provided responses to a Type B meeting package. Oragenics still targets an IND submission by end-2026.
NYSE American deficiency notice over stockholders’ equity shortfall
Oragenics received an NYSE American deficiency letter on Aug. 26 for failing stockholders’ equity continued listing standards.
The notice cited Sections 1003(a)(ii) and 1003(a)(iii), tied to equity thresholds for issuers with multi-year operating losses.
The company has 45 days to submit a compliance plan; acceptance would allow continued listing during a cure period.
Delisting procedures could start if the plan is not submitted, not accepted, or compliance is not restored by Feb. 25, 2028.
